A Study on the Impact of Online Positive Psychological Intervention on the Mental Health and Quality of Life of Crohn's Disease Patients

NCT06939712 · tracked via the Priya Life Science China tracker

Sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine

Phase

Not applicable

Started

2025-05-01

Last updated

2025-07-15

Condition(s) studied

Crohn Disease

Investigational drug(s) / intervention(s)

Online Positive Psychology InterventionRoutine Care

Online Positive Psychology Intervention: A 6-week online psychological support program, held once a week, primarily organized by a facilitator, with patient-led discussions and communication.

Routine Care: A 6-week program of health education provided by IBD specialists and nurses during patient follow-ups, tailored to individual patient circumstances and needs. Topics include IBD disease knowledge, medication management, diet, exercise, lifestyle, psychological support, and follow-up care. Patients in this group will also join a control group WeChat group for study-related communication.

Study summary

Crohn's disease (CD) is a chronic, nonspecific inflammatory disease that can affect the entire digestive tract. It is difficult to cure and often relapses, causing long-term suffering for patients. This persistent condition significantly impacts their mental and psychological well-being, leading to a noticeable decline in their quality of life. Furthermore, these negative emotions can contribute to disease recurrence and the worsening of symptoms. Positive psychological intervention (PPI) refers to the enhancement of positive emotions, cognition, and behaviors to increase well-being and alleviate symptoms. Therefore, this study aims to use psychological methods to help CD patients better recognize and understand their positive experiences, thus aiding them in coping with stress and adversity more effectively.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Patients diagnosed with Crohn's disease according to the 2018 diagnostic criteria established by the Inflammatory Bowel Disease Group of the Chinese Medical Association's Gastroenterology Branch; * Patients aged between 18 and 75 years; * Patients with a score of 5-14 on the GAD-7 (indicative of mild to moderate anxiety) or a score of 5-14 on the PHQ-9 (indicative of mild to moderate depression); * Patients who understand and agree to comply with the study requirements and have signed informed consent; * Patients who are able to read and access the internet, either independently or with assistance from a family member, and are capable of using WeChat and mobile applications; * Patients who are able to complete all course trainings and/or follow-up procedures. Exclusion Criteria: * Individuals with a history or current diagnosis of psychiatric illness or cognitive impairment, or those currently taking psychiatric medications; Individuals working in the field of psychology, or those who have previously studied or are currently studying positive psychology; * Individuals with concurrent other intestinal diseases or malignancies; * Individuals with severe primary diseases of the cardiovascular, cerebrovascular, hepatic, or renal systems. Withdrawal Criteria: * Patients lost to follow-up due to withdrawal or other reasons during the intervention period; * Patients who develop severe complications or experience significant changes in their condition that prevent them from continuing the study.

Primary outcome measure(s)

GAD-7 — Measurements will be conducted at four time points: prior to the intervention, at the end of Week 3 of the intervention, at the end of Week 6 of the intervention, and three months after the intervention concludes.
indicative of mild to moderate anxiety

Trial sites (1)

Facility	City	Region	Status
The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou	Hangzhou	Zhejiang	Recruiting

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma Enrolling by invitation

Evaluating Presbyopia-Correcting IOLs in Complex Cataract Cases With Anterior Segment Abnormalities Recruiting

The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer Enrolling by invitation

A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa Starting soon

The Effect of Good Limb Position Management Assistive Devices on Preventing Shoulder Subluxation in Hemiplegic Patients Active, not recruiting

Other trials for the same condition

Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease Recruiting

Effect of Acupuncture on Mild to Moderate Active Crohn's Disease Recruiting

Investigation of the Correlation Between Polyamine Levels and Their Key Enzymatic Activities in Association With Inflammatory Bowel Disease Progression Recruiting

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Recruiting

Comparing Endoscopic Strictureplasty vs. Balloon Dilation in Crohn's Disease Strictures Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06939712 on ClinicalTrials.gov ↗ ← All trials in China